THINK Surgical, an innovator in the field of orthopedic surgical robots, today announced that its TMINI Miniature Robotic System has received 510(k) clearance from the US Food and Drug Administration (FDA) for use with the LinkSymphoKnee (LSK) from Waldemar Link GmbH & Co. KG, Germany (LINK) under a Collaboration Agreement between the two companies.
The LinkSymphoKnee has been added to THINK Surgical’s ID-HUB, a proprietary data bank of implant modules for use with the open platform version of its TMINI System in the United States.
“At LINK, we have always prioritized innovation in orthopedic solutions, focusing on how we can empower our customers—the surgeons—with tools that can be used to elevate precision, adaptability, and patient outcomes,” said Peter Willenborg, chief executive officer of LINK.
Greg Pomasl, president of LINK in the USA (LinkBio Corporation), added, “Through this partnership, we’re not only providing a state-of-the-art robotic solution but a nimble, cost-effective, hand-held option that complements the full spectrum of our LinkSymphoKnee primary products,” said Pomasl. “With LinkSymphoKnee and the TMINI System, we are setting a new standard in knee surgery support, ensuring our customers have the most advanced tools available to deliver exceptional patient care.”
“THINK Surgical is excited to add the LinkSymphoKnee to the TMINI System. The open platform version of TMINI is now available with eight different knee designs from eight separate orthopedic companies offering surgeons the choice of single-radius, anatomic, and guided motion knees on a single robotic platform.” said Stuart Simpson, president, and chief executive officer of THINK Surgical.
